

Arena Pharmaceuticals, Inc.

Metabolic Disease • Cardiovascular Disease • Immunology

DELEGATE(S) Xiao-Xiong Lu, PhD, Chief Business Officer, Asia Pacific

6154 Nancy Ridge Drive
San Diego, CA 92121
USA

www.arenapharm.com

Incorporated: 1997

Employees: 350

Ownership: Public

NASDAQ: ARNA

MISSION/BACKGROUND

Arena, a NASDAQ listed clinical-stage biopharmaceutical company of 300+ employees, was founded in 1997 and is located in San Diego with a manufacturing subsidiary in Switzerland. Arena is focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), an important class of validated drug targets, in the therapeutic areas of metabolic, cardiovascular, inflammatory and CNS diseases. Lorcaserin, a selective 5HT2C agonist intended for weight management, is our most advanced drug candidate. After completing a pivotal Phase 3 clinical trial program, we submitted an NDA to US FDA in Dec 2009 and the FDA issued a Complete Response Letter (CRL) in Oct 2010. We plan to submit a response to the CRL around end of 2011 and

submit an MAA to the EMA in early 2012. Lorcaserin was discovered/developed by Arena and partnered with Eisai US at a late stage. Pending regulatory approvals, we intend to commercialize Lorcaserin in the US with Eisai and in other markets independently or with other companies. Our other drug candidates include: temanogrel (Phase 2-ready), a serotonin 5HT2A antagonist intended for acute myocardial infarction, acute coronary syndrome and other cardiovascular conditions; GPR119 agonists intended for type 2 diabetes which include APD597 (Phase 2-ready) and next-generation agonists in preclinical development; APD811 (in Phase 1), a prostacyclin agonist intended for pulmonary arterial hypertension (PAH); APD334 (in late preclinical development), an S1P1 agonist intended for multiple sclerosis and other autoimmune diseases; a cannabinoid 2 (CB2) agonist (in preclinical development) intended for osteoarthritis and/or neuropathic pain. In addition to our current partnership with Eisai, Arena has had extensive partnering experience, including collaborations with Merck and J&J. We intend to continue to advance our pipeline independently or through licensing deals, collaborations and other business relationships.

TECHNOLOGY

Arena's drug candidates have resulted from their GPCR-focused drug discovery and development approach, specialized expertise and technologies.

ALLIANCES

Arena has a Marketing and Supply Agreement with Eisai Inc. through which Eisai is granted exclusive commercialization rights for Lorcaserin in the United States.

PRODUCTS			
<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
Lorcaserin	NDA/BLA filed, or in process	Weight management	Arena response to FDA CRL around end of 2011
Temanogrel	Phase I	acute myocardial infarction, acute coronary syndrome and other CV conditions	Phase 1a/1b completed, Phase 2 plan available
APD597	Phase I	Type 2 diabetes	3 Phase 1 trials completed
APD811	Phase I	Pulmonary arterial hypertension (PAH)	Phase 1a completed
APD334	Preclinical	Multiple sclerosis and other autoimmune diseases	IND planned for 2012
CB2 Agonist	Preclinical	Osteoarthritis and/or neuropathic pain	IND enabling tox in 2012
GPR119 Agonists	Optimized Lead	Type 2 diabetes	Candidate for preclinical development in 2012